Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) EBITDA (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of EBITDA data on record, last reported at $2.3 million in Q3 2025.

  • For Q3 2025, EBITDA fell 54.85% year-over-year to $2.3 million; the TTM value through Sep 2025 reached $11.8 million, down 32.2%, while the annual FY2024 figure was $12.6 million, 29.92% down from the prior year.
  • EBITDA reached $2.3 million in Q3 2025 per UTMD's latest filing, down from $4.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $6.9 million in Q4 2022 and bottomed at $884000.0 in Q4 2024.
  • Average EBITDA over 5 years is $3.6 million, with a median of $3.4 million recorded in 2021.
  • Peak YoY movement for EBITDA: skyrocketed 329.81% in 2021, then plummeted 84.29% in 2024.
  • A 5-year view of EBITDA shows it stood at $4.1 million in 2021, then skyrocketed by 67.53% to $6.9 million in 2022, then fell by 19.0% to $5.6 million in 2023, then tumbled by 84.29% to $884000.0 in 2024, then soared by 155.09% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $2.3 million in Q3 2025, $4.9 million in Q2 2025, and $3.8 million in Q1 2025.